PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMeropenem
Merrem iv, Vaborem(meropenem)
Meropenem, Merrem, Vabomere, Vaborem (meropenem) is a small molecule pharmaceutical. Meropenem was first approved as Merrem iv on 1996-06-21. It is used to treat appendicitis, bacterial infections, bacteroides infections, escherichia coli infections, and fever amongst others in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Meropenem (discontinued: Meropenem, Merrem)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meropenem
Tradename
Company
Number
Date
Products
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINERB. Braun MedicalN-202106 RX2015-04-30
2 products
MEROPENEMHQ Specialty PharmaN-215212 RX2023-07-26
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
meropenemANDA2025-09-16
meropenem and sodium chlorideNew Drug Application2025-08-05
meropenem meropenemANDA2019-05-24
vabomereNew Drug Application2025-03-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
respiratory tract infections—D012141J06.9
neutropenia—D009503D70
fever—D005334R50.9
urinary tract infectionsEFO_0003103D014552N39.0
bacterial infections—D001424A49
appendicitisEFO_0007149D001064K37
pseudomonas infectionsEFO_0001076D011552A41.52
escherichia coli infectionsEFO_1001318D004927B96.20
soft tissue infections—D018461—
peritonitisEFO_0008588D010538K65
Show 5 more
Agency Specific
FDA
EMA
Expiration
Code
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX
2027-08-29GAIN
2022-08-29NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Meropenem / Vaborbactam, Vabomere, Rempex
113762372039-04-06U-3421
86801362031-08-29DS, DP
96940252031-08-08U-2120
101728742031-08-08DP
101830342031-08-08U-2490
105616752031-08-08U-2490
110072062031-08-08U-3128
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DH: Carbapenems
— J01DH02: Meropenem
— J01DH52: Meropenem and vaborbactam
HCPCS
Code
Description
J2184
Injection, meropenem (b. braun) not therapeutically equivalent to j2185, 100 mg
J2185
Injection, meropenem, 100 mg
J2186
Injection, meropenem and vaborbactam, 10mg/10mg (20mg)
Clinical
Clinical Trials
251 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0—11——2
Intraabdominal infectionsD059413————2——2
SepsisD018805EFO_0001420A41.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
InfectionsD007239EFO_0000544—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMeropenem
INNmeropenem
Description
Meropenem is a carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively. It has a role as an antibacterial drug, an antibacterial agent and a drug allergen. It is a carbapenemcarboxylic acid, a pyrrolidinecarboxamide, an alpha,beta-unsaturated monocarboxylic acid and an organic sulfide.
Classification
Small molecule
Drug classantibacterial antibiotics, carbapenem derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
Identifiers
PDB—
CAS-ID96036-03-2
RxCUI—
ChEMBL IDCHEMBL127
ChEBI ID43968
PubChem CID441130
DrugBankDB00760
UNII IDYOP6PX0BAO (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Merrem – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Meropenem
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 50,225 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16,828 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use